Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
China Resources Pharmaceutical Group Ltd. announced a change in its company secretary and authorized representative, effective December 15, 2025. Ms. Cheng Kwai Yuk resigned from her roles, with no disagreements with the board, and Ms. Wan Wing Yi Carol, who has extensive experience in corporate secretarial services, has been appointed as her successor. This transition is expected to maintain the company’s governance standards and ensure continued compliance with Hong Kong Stock Exchange regulations.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is a significant player in the Chinese market, offering a wide range of medical and healthcare products.
YTD Price Performance: -16.89%
Average Trading Volume: 14,735,023
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.96B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.